We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)
News

Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)

Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)
News

Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm Group™ (Debiopharm) has announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

The aim of the study is to identify the dose limiting toxicity (DLT) and to estimate the maximal tolerated dose (MTD) of Debio 1347 (CH5183284) based on the safety and tolerability of the product during a daily oral administration to patients suffering from advanced solid malignancies that have an alteration of the FGFR 1, 2 or 3 genes (fibroblast growth factor receptor).

During an expansion part, the study will also evaluate the safety profile at the recommended dose of Debio 1347 (CH5183284) in a larger cohort of patients.

“We are delighted to initiate this first clinical phase I study with Debio 1347 (CH5183284)” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group. “Debio 1347 (CH5183284) is going to be developed with a companion diagnostic and we believe it could become a personalized treatment option for patients suffering from solid tumors which could significantly improve their outcomes”.

In December 2012, Debiopharm signed an exclusive license agreement with Chugai Pharmaceutical Co., Ltd for the development and commercialization of Debio 1347 (CH5183284) in all countries worldwide including Japan.

Eight months after executing the deal, Debio 1347 (CH5183284) is being tested in a phase I in several oncology centers of excellence in the USA and Europe.

Advertisement